Breast最新文献

{"title":"Atypical ductal or lobular hyperplasia, lobular carcinoma in-situ, flat epithelial atypia, and future risk of developing breast cancer: Systematic review and meta-analysis","authors":"Jannah Baker ,&nbsp;Naomi Noguchi ,&nbsp;M Luke Marinovich ,&nbsp;Brian L. Sprague ,&nbsp;Elizabeth Salisbury ,&nbsp;Nehmat Houssami","doi":"10.1016/j.breast.2024.103807","DOIUrl":"10.1016/j.breast.2024.103807","url":null,"abstract":"<div><h3>Background</h3><p>Biopsy-proven breast lesions such as atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS) and flat epithelial atypia (FEA) increase subsequent risk of breast cancer (BC), but long-term risk has not been synthesized. A systematic review was conducted to quantify future risk of breast cancer accounting for time since diagnosis of these high-risk lesions.</p></div><div><h3>Methods</h3><p>A systematic search of literature from 2000 was performed to identify studies reporting BC as an outcome following core-needle or excision biopsy histology diagnosis of ADH, ALH, LCIS, lobular neoplasia (LN) or FEA. Meta-analyses were conducted to estimate cumulative BC incidence at five-yearly intervals following initial diagnosis for each histology type.</p></div><div><h3>Results</h3><p>Seventy studies reporting on 47,671 subjects met eligibility criteria. BC incidence at five years post-diagnosis with a high-risk lesion was estimated to be 9.3 % (95 % CI 6.9–12.5 %) for LCIS, 6.6 % (95 % CI 4.4–9.7 %) for ADH, 9.7 % (95 % CI 5.3–17.2 %) for ALH, 8.6 % (95 % CI 6.5–11.4 %) for LN, and 3.8 % (95 % CI 1.2–11.7 %) for FEA. At ten years post-diagnosis, BC incidence was estimated to be 11.8 % (95 % CI 9.0–15.3 %) for LCIS, 13.9 % (95 % CI 7.8–23.6 %) for ADH, 15.4 % (95 % CI 7.2–29.3 %) for ALH, 17.0 % (95 % CI 7.2–35.3 %) for LN and 7.2 % (95 % CI 2.2–21.2 %) for FEA.</p></div><div><h3>Conclusion</h3><p>Our findings demonstrate increased BC risk sustained over time since initial diagnosis of high-risk breast lesions, varying by lesion type, with relatively less evidence for FEA.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103807"},"PeriodicalIF":5.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001383/pdfft?md5=90f4ed83118422b63c55aacd89e17b30&pid=1-s2.0-S0960977624001383-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of different exercise types on quality of life in patients with breast cancer: A network meta-analysis of randomized controlled trials","authors":"Liang Li,&nbsp;Yutong Wang,&nbsp;Mingzhou Cai,&nbsp;Tonggang Fan","doi":"10.1016/j.breast.2024.103798","DOIUrl":"10.1016/j.breast.2024.103798","url":null,"abstract":"<div><h3>Background</h3><p>Exercise is a rehabilitation strategy for patients with breast cancer; however, the optimal type of exercise remains uncertain. This study aimed to compare the effects of five exercise types on the quality of life of patients with breast cancer and provide a basis for their exercise rehabilitation.</p></div><div><h3>Methods</h3><p>As of May 2024, we searched four databases: Embase, PubMed, Web of Science, and Cochrane Library, and included randomized controlled trials that analyzed the effect of exercise on the quality of life of patients with breast cancer. A network meta-analysis was performed using a frequency-based framework.</p></div><div><h3>Results</h3><p>Forty-five papers involving 4092 participants were included. The five types of exercises included were all significant in the direct comparison with the control group, except yoga and mind–body exercises. Aerobic, resistance, and combination exercises were associated with quality of life. However, in indirect comparisons, only mind–body exercise versus resistance exercise had a significant effect. The effect of exercise on the quality of life(total health status) of patients with breast cancer was ranked based on surface under the cumulative ranking curve (SUCRA) values combined with effect sizes as follows: aerobic exercise (SUCRA = 84.1) &gt; combined exercise (SUCRA = 78.8) &gt; resistance exercise (SUCRA = 66.4) &gt; yoga (SUCRA = 39.3) &gt; mind-body exercise (SUCRA = 27.2) &gt; usual care (SUCRA = 4.1).</p></div><div><h3>Conclusions</h3><p>Exercise can rehabilitate the quality of life of patients with breast cancer, and aerobic exercise may be the best type of exercise to improve their quality of life(total health status).</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103798"},"PeriodicalIF":5.7,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001292/pdfft?md5=12013e3b0e68510d8c11bc049a75bd6e&pid=1-s2.0-S0960977624001292-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic body radiotherapy using CyberKnife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of dosimetric characteristics and preliminary clinical results","authors":"Ting-Na Wei ,&nbsp;Jia-Fu Lin ,&nbsp;Mei-Chun Cheng ,&nbsp;Hui-Ling Yeh","doi":"10.1016/j.breast.2024.103796","DOIUrl":"10.1016/j.breast.2024.103796","url":null,"abstract":"<div><h3>Introduction</h3><p>We compared the dosimetric characteristics of the target and organs at risk (OARs) as well as the preliminary clinical outcomes between two accelerated partial breast irradiation (APBI) techniques.</p></div><div><h3>Methods</h3><p>Forty-four patients diagnosed with left-sided early breast cancer who underwent APBI using either interstitial brachytherapy (IB) or stereotactic body radiation therapy (SBRT) with CyberKnife (CK) were retrospectively reviewed. The dosimetric parameters of the target and OARs were compared. Preliminary clinical outcomes, including tumor control and acute toxicity, were analyzed.</p></div><div><h3>Results</h3><p>Treatment plans with CK demonstrated a better cardiac dose-sparing effect. Radiation doses to the heart at V_150cGy for the CK and IB groups were 24.4 % and 60.4 %, respectively (<em>p</em> &lt; 0.001), while the mean heart doses for the CK and IB groups were 107.4 cGy and 204 cGy, respectively (<em>p</em> &lt; 0.001). The heart D_1c.c. and the ipsilateral lung received a lower dose in the IB group, without any significant differences. The median follow-up time in the CK and IB groups was 28.6 and 61.3 months, respectively. No patients died from either breast cancer or cardiac events during follow-up. A locoregional recurrence event at the neck occurred in one patient within the IB group.</p></div><div><h3>Conclusions</h3><p>APBI planned by CK was shown to have a better dose-sparing effect on the heart, as well as better conformity and homogeneity to the target. CK is a non-invasive treatment which showed minimal acute toxicity and promising tumor control.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103796"},"PeriodicalIF":5.7,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001279/pdfft?md5=c187a162a0112bd2369b3e57ba9a8251&pid=1-s2.0-S0960977624001279-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can we counterbalance restricted access to innovation through specialized breast cancer care? The REAL-NOTE study","authors":"Leonor Vasconcelos de Matos,&nbsp;Marcio Debiasi,&nbsp;Teresa Gantes Padrão,&nbsp;Berta Sousa,&nbsp;Fatima Cardoso","doi":"10.1016/j.breast.2024.103793","DOIUrl":"10.1016/j.breast.2024.103793","url":null,"abstract":"<div><h3>Introduction</h3><p>The KEYNOTE-522 (KN-522) trial showed that the addition of pembrolizumab to standard chemotherapy improved pathological complete response (pCR) and event-free survival (EFS) for patients with early triple negative breast cancer (TNBC). We analyzed results of a real-world cohort of patients treated in a certified Breast Unit, before the introduction of pembrolizumab, to see if high quality care can match outcomes brought by the addition of an innovative anticancer therapy.</p></div><div><h3>Methods</h3><p>Observational, retrospective, single-center cohort study, with real-world data from an ongoing institutional database with prespecified variables. Inclusion criteria matched the ones from KN-522: previously untreated stage II or III TNBC, diagnosed between 2012 and 2022, who received neoadjuvant chemotherapy. The primary endpoints were pCR at the time of definitive surgery and EFS; overall survival (OS) was a secondary endpoint.</p></div><div><h3>Results</h3><p>Total of 168 patients were included, median age 55 years, 55 % received neoadjuvant chemotherapy with dose dense anthracyclines and taxanes and 25 % carboplatin + paclitaxel, sequenced with dose dense anthracyclines. Most had Stage II disease (82.7 %), 47 % node + disease. pCR was achieved in 52.7 % cases. At 36 months, EFS was 83.3 % (95 % CI 75.1–89.0) and OS 89 % (95 % CI, 81.6 to 93.5).</p></div><div><h3>Conclusions</h3><p>Notwithstanding the study limitations, outcomes of patients treated with chemotherapy without immunotherapy were numerically similar to the experimental arm of KN-522 trial. These data highlight that providing care by a specialized multidisciplinary team in a certified unit might be just as impactful as the incorporation of new technologies.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103793"},"PeriodicalIF":5.7,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001243/pdfft?md5=6cd6e5f7dd636269087cdf6cdf0927ac&pid=1-s2.0-S0960977624001243-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142129692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metronomic chemotherapy using capecitabine and cyclophosphamide in metastatic breast cancer – efficacy, tolerability and quality of life results from the phase II METRO trial","authors":"Karolina Larsson F ,&nbsp;Jamila Adra ,&nbsp;Leif Klint ,&nbsp;Barbro Linderholm","doi":"10.1016/j.breast.2024.103795","DOIUrl":"10.1016/j.breast.2024.103795","url":null,"abstract":"<div><h3>Background</h3><p>Chemotherapy is commonly used in metastatic breast cancer (MBC) to prolong life and improve quality of life (QoL). The optimal dosing and sequencing beyond the second line of treatment are unknown and pose a risk of overtreatment. Continuous low oral doses of metronomic chemotherapy using capecitabine 500 mg three times daily and cyclophosphamide 50 mg once daily (MCT-CX) may be an effective and tolerable treatment option for patients with MBC.</p></div><div><h3>Methods</h3><p>In this open-label, single-arm single-centre phase II trial patients with MBC received MCT-CX until disease progression or unacceptable toxicity. The primary endpoint was the clinical benefit rate (CBR), defined as the proportion of participants with a best overall response of complete (CR) or partial response (PR) at any time, or stable disease (SD) for ≥24 weeks according to radiological evaluation. Toxicity was assessed according to the Common Toxicity Criteria v 4.0. QoL was assessed with the EORTC-30 questionnaire.</p></div><div><h3>Results</h3><p>In total, 40 patients were included. Most participants (72 %) presented with visceral disease and received MCT-CX beyond the second line (58 %). The CBR was 45 % (8 PR and 10 SD ≥ 24 weeks). Toxicities were low grade with hand-foot syndrome being the most common. There was no significant change in QoL over the first 24 weeks.</p></div><div><h3>Conclusion</h3><p>MCT-CX is a plausible treatment option in far advanced breast cancer, with almost half of trial participants responding to treatment without QoL impairments.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103795"},"PeriodicalIF":5.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001267/pdfft?md5=8a1f551759b97a4eb9f8fa1c662ca0e0&pid=1-s2.0-S0960977624001267-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142135883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Body composition in early breast cancer patients treated with adjuvant aromatase inhibitors: Does dietary counseling matter?","authors":"Rebecca Pedersini ,&nbsp;Greta Schivardi ,&nbsp;Marta Laganà ,&nbsp;Lara Laini ,&nbsp;Pierluigi di Mauro ,&nbsp;Manuel Zamparini ,&nbsp;Vito Amoroso ,&nbsp;Alessia Bonalumi ,&nbsp;Sara Bosio ,&nbsp;Barbara Zanini ,&nbsp;Chiara Buizza ,&nbsp;Nicole Villa ,&nbsp;Marco Ravanelli ,&nbsp;Luca Rinaudo ,&nbsp;Salvatore Grisanti ,&nbsp;Davide Farina ,&nbsp;Alfredo Berruti ,&nbsp;Francesco Donato ,&nbsp;Deborah Cosentini","doi":"10.1016/j.breast.2024.103794","DOIUrl":"10.1016/j.breast.2024.103794","url":null,"abstract":"<div><h3>Purpose</h3><p>The impact of dietary counseling on body composition in early breast cancer patients (EBC) treated with aromatase inhibitors (AIs) is uncertain. The aim of this study was to assess the effects of a diet counseling program on weight, BMI, total and regional body composition in patients treated with AIs.</p></div><div><h3>Methods</h3><p>This observational study involved 194 EBC patients, of which 97 attended a 6-month personalized counseling program, based on Mediterranean diet principles (cohort A) and 97 did not (cohort B). Dual-energy X-ray absorptiometry (DXA) scan was used to measure the total and regional fat and lean body mass, before (baseline) and after at least 18 months of AI-therapy.</p></div><div><h3>Results</h3><p>Weight and BMI increased significantly, on the average, in cohort B, but not in cohort A. In the cohorts A and B, fat mass increased by 10 % and 7.7 % respectively, while lean mass decreased by 3.3 % and 2.6 % from before to after AI therapy, without statistically significant differences between them using the Mann-Whitney test. The changes in body composition were greater in premenopausal than in postmenopausal women at cancer diagnosis. The proportion of patients with sarcopenia, obesity and sarcopenic obesity increased from before to after AI therapy, similarly in both cohorts.</p></div><div><h3>Conclusions</h3><p>Patients treated with AIs reported an increase in fat mass and a decrease in lean mass, and consequently an increase in sarcopenia and obesity, regardless of the participation in a dietary counseling program. A combined dietary counseling and physical exercise program may be necessary for preventing these unfavourable changes in these patients.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103794"},"PeriodicalIF":5.7,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001255/pdfft?md5=f437acc4e97a2981d1fd11190f103a15&pid=1-s2.0-S0960977624001255-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142168958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy","authors":"Lei Ji ,&nbsp;Xi Chen ,&nbsp;Xiaoyan Qian,&nbsp;Min Xiao,&nbsp;Qing Li,&nbsp;Qiao Li,&nbsp;Jiayu Wang,&nbsp;Ying Fan,&nbsp;Yang Luo,&nbsp;Shanshan Chen,&nbsp;Fei Ma,&nbsp;Binghe Xu,&nbsp;Pin Zhang","doi":"10.1016/j.breast.2024.103792","DOIUrl":"10.1016/j.breast.2024.103792","url":null,"abstract":"<div><h3>Background</h3><p>The majority of HR+/HER2-breast cancer patients can also achieve long-term survival despite not attaining pCR, indicating limited prognostic value of pCR in this population. This study aimed to identify novel pathologic end points for predicting long-term outcomes in HR+/HER2-breast cancer after neoadjuvant chemotherapy.</p></div><div><h3>Methods</h3><p>We analyzed HR+/HER2-breast cancer patients with stage II-III tumors who underwent curative surgery after neoadjuvant chemotherapy from three hospitals. Major pathologic response (MPR), defined as the presence of Miller-Payne grades 3–5 and positive lymph node ratio of ≤10 %, was used as a pathological evaluation indicator. We assessed the association between MPR and event-free survival (EFS) and performed Multivariable Cox regression to identify independent factors associated with EFS.</p></div><div><h3>Results</h3><p>From January 2010 to December 2020, 386 patients were included in the final analysis. 28 patients (7.3 %) achieved pCR and 118 patients (30.6 %) achieved MPR. The median duration of follow-up was 54.4 months,5-year EFS was 87 % in the MPR group vs. 68 % in the non-MPR group. Multivariate analysis showed that low PR expression, high clinical stage, lower Miller–Payne grades and Positive lymph node ratio were independent poor prognostic factors for EFS (all <em>P</em> values &lt; 0.05). The prognostic effect of MPR remained in multivariable models (hazard ratio (HR), 0.45; 95 % confidence interval (CI), 0.26–0.76; P = 0.008), In non-pCR patients, those who achieved MPR exhibited a similar EFS compared with pCR patients (HR, 2.25; 95 % CI, 0.51–9.84; P = 0.28).</p></div><div><h3>Conclusion</h3><p>MPR may be a novel pathologic end point in HR+/HER2-breast cancer after neoadjuvant chemotherapy, holding greater applicability in the prognosis evaluation than pCR.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103792"},"PeriodicalIF":5.7,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001231/pdfft?md5=dce3d644e7cae1158e86caa08273db64&pid=1-s2.0-S0960977624001231-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142129635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world prevalence, treatment and survival of “high risk” early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry","authors":"Sylvain Ladoire ,&nbsp;Ariane Mamguem Kamga ,&nbsp;Loick Galland ,&nbsp;Isabelle Desmoulins ,&nbsp;Didier Mayeur ,&nbsp;Courèche Kaderbhai ,&nbsp;Silvia Mihaelia Ilie ,&nbsp;Audrey Hennequin ,&nbsp;Clementine Jankowski ,&nbsp;Juliette Albuisson ,&nbsp;Sophie Nambot ,&nbsp;Charles Coutant ,&nbsp;Laurent Arnould ,&nbsp;Manon Reda ,&nbsp;Caroline Truntzer ,&nbsp;Sandrine Dabakuyo","doi":"10.1016/j.breast.2024.103789","DOIUrl":"10.1016/j.breast.2024.103789","url":null,"abstract":"<div><h3>Background</h3><p>The results of the OlympiA study led to the approval of a PARP inhibitor (olaparib) as adjuvant treatment for early breast cancer (eBC) at high risk of relapse in patients with a germline BRCA1/2 mutation (gBRCAm). However, the proportion of patients in routine practice who meet the “high-risk” criteria applied in the OlympiA study, and for whom gBRCAm testing would now be mandatory, remains unknown.</p></div><div><h3>Patients and methods</h3><p>In this population-based study, we use unique data from the French specialized Côte d'Or Breast and Gynecological Cancer Registry, to assess the real-life proportion, and long-term prognosis of patients treated for eBC between 2005 and 2015 with standard treatment, and at “high risk” of relapse according to the OlympiA trial criteria.</p></div><div><h3>Results</h3><p>We included 3483 patients treated for HER2-negative eBC (N = 380 with ER-, and N = 3103 with ER + tumor). We found N = 62 (1.8 %) patients with gBRCA1/2 mutations. A total of 494 patients (14.2 %) were classified as “high risk” according to the Olympia criteria; 55 % with ER-tumors, and 9.1 % with ER + tumors, respectively. Despite more intensive systemic treatments in “high risk” patients, 10-year overall survival was much worse in these “high risk” patients compared to the others: 60.1 % vs 83.8 % in ER-tumors, and 55.4 % vs 84.1 % in ER + tumors. Our estimates of net survival show an even greater difference.</p></div><div><h3>Conclusion</h3><p>This study provides real-life insights into the prevalence and prognosis of patients with high-risk eBC, in a context where the approval of adjuvant olaparib requires careful reorganization of care, so as not to overlook a patient with gBRCAm who could benefit from adjuvant olaparib.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103789"},"PeriodicalIF":5.7,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001206/pdfft?md5=d184e8c1a802c61b7c94af45e2814925&pid=1-s2.0-S0960977624001206-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Locoregional recurrence in studies of primary systemic therapy in early invasive breast cancer","authors":"Luqi Chen ,&nbsp;Stuart A. McIntosh ,&nbsp;Siddharth Tyagi ,&nbsp;David Dodwell","doi":"10.1016/j.breast.2024.103791","DOIUrl":"10.1016/j.breast.2024.103791","url":null,"abstract":"<div><h3>Introduction</h3><p>The use of primary systemic therapy (PST) in early invasive breast cancer is routine but there are concerns about risk of locoregional recurrence.</p></div><div><h3>Methods</h3><p>We conducted a systematic literature review to identify studies of locoregional treatment and recurrence in patients with early invasive breast cancer who received non-endocrine PST.</p></div><div><h3>Results</h3><p>We identified 112 studies (18 prospective trials and 94 non-interventional studies). The use of surgery and radiotherapy after PST was recorded in 65 (58 %) and 50 (45 %) of studies respectively. 66 (59 %) studies reported locoregional recurrence. Cumulative 5-year locoregional recurrence risks varied from 1 % to 23 %. Locoregional recurrence was higher in patients under the age of 40, those who did not achieve a pathological complete remission after PST, had ER-negative or HER2 negative tumours, were recorded to have inoperable disease before PST, and did not have radiotherapy. LRR rates in these studies have not fallen over the overall calendar period of patient enrollment (1999–2016).</p></div><div><h3>Conclusion</h3><p>The recording of locoregional treatments and outcomes is suboptimal in studies of PST and efforts to improve this are required. In the absence of randomised evidence, our findings may help to inform care and guideline development. We were unable to exclude concern that the use of PST is associated with a higher than desired risk of locoregional recurrence.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"77 ","pages":"Article 103791"},"PeriodicalIF":5.7,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S096097762400122X/pdfft?md5=b294adef2876db4049c889b722506a3c&pid=1-s2.0-S096097762400122X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142096085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Perspective: An integrated vision of the quality of life in breast cancer survivorship trajectory”","authors":"Chiara Marzorati ,&nbsp;Marianna Masiero ,&nbsp;Gabriella Pravettoni","doi":"10.1016/j.breast.2024.103785","DOIUrl":"10.1016/j.breast.2024.103785","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"77 ","pages":"Article 103785"},"PeriodicalIF":5.7,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001164/pdfft?md5=f4c4158137f344f64e5bbdb95dc803cf&pid=1-s2.0-S0960977624001164-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142088013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}